NCT00642499

Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

A Double-Blind, Randomized, Parallel-Group, Pilot Study of Oral Dronabinol Versus Placebo in the Treatment or Prevention of Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 103 (actual)
• Sponsor: Solvay Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this study is to determine if dronabinol is effective in preventing or treating nausea caused by HAART (highly active anti-retroviral therapy) in HIV and AIDS patients

Conditions

• Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting
• HIV Infections

Interventions

Type	Name	Description
DRUG	Dronabinol	2.5 mg to 40 mg
DRUG	Placebo	placebo

Timeline

• Start date: 2003-08-01
• Primary completion: 2005-04-01
• Completion: 2005-04-01
• First posted: 2008-03-25
• Last updated: 2008-04-02

Locations

36 sites across 1 country: United States